Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PI4KA | P42356 | 1/20 | 0.52 |
| ▸ | PI4K2B | Q8TCG2 | 1/20 | 0.52 |
| ▸ | PI4K2A | Q9BTU6 | 1/20 | 0.52 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.52 |
| ▸ | MAP4K4 | O95819 | 9/20 | 0.49 |
| ▸ | CLK1 | P49759 | 2/20 | 0.49 |
| ▸ | LIMK1 | P53667 | 2/20 | 0.49 |
| ▸ | EGFR | P00533 | 1/20 | 0.45 |
| ▸ | TGFBR1 | P36897 | 4/20 | 0.44 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.43 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.43 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.43 |
| ▸ | CDC7 | O00311 | 1/20 | 0.43 |
| ▸ | DBF4 | Q9UBU7 | 1/20 | 0.43 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL30575851 | 0.98 | PI4KA (0.50) | PI4KAPI4K2BPI4K2API4KBMAP4K4 | |
| SCHEMBL31065817 | 0.79 | PRMT5 (0.41) | MAP4K4CLK1LIMK1PRMT5 | |
| SCHEMBL30946645 | 0.74 | EGFR (0.45) | EGFR | |
| SCHEMBL30831917 | 0.74 | PDE4A (0.52) | EGFR | |
| SCHEMBL3237268 | 0.74 | EGFR (0.45) | EGFR | |
| SCHEMBL13454691 | 0.74 | HSP90AA1 (0.45) | MAP4K4EGFRTGFBR1PRMT5 | |
| SCHEMBL7876 | 0.74 | PDE4A (0.52) | EGFR | |
| SCHEMBL12560186 | 0.74 | EGFR (0.49) | MAP4K4EGFRPRMT5 | |
| SCHEMBL29517215 | 0.72 | DHFR (0.54) | ADORA2APRMT5 | |
| SCHEMBL3617192 | 0.72 | DHFR (0.54) | ADORA2APRMT5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 79 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220274979-A1 | 2-METHYL-AZA-QUINAZOLINES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2022-09-01 | — | — | US | claimed |
| EP-3976609-A1 | PYRIDOPYRIMIDINES DERIVATIVES AS P2X3 INHIBITORS | Chiesi Farmaceutici S.p.A. (IT) | 2022-04-06 | — | — | EP | claimed |
| CN-114222741-A | As P2X3Suppression ofPyridopyrimidine derivatives as agents | 奇斯药制品公司 | 2022-03-22 | — | — | CN | claimed |
| EP-2614061-B1 | QUINOLINE AND QUINOXALINE DERIVATIVES AS KINASE INHIBITORS | UCB PHARMA SA (BE) | 2015-05-20 | — | — | EP | claimed |
| US-12617789-B2 | Small molecular inhibitors of NF-κb inducing kinase | JANSSEN PHARMACEUTICA NV (BE) | 2026-05-05 | — | — | US | disclosed |
| US-20250129078-A1 | ERBB2 INHIBITORS | COGENT BIOSCIENCES, INC. | 2025-04-24 | — | — | US | disclosed |
| EP-4476211-A1 | ACYLATED HETEROCYCLIC QUINAZOLINE DERIVATIVES AS INHIBITORS OF ERBB2 | Enliven Inc. (US) | 2024-12-18 | — | — | EP | disclosed |
| US-20240327435-A1 | AMINO-SUBSTITUTED HETEROCYCLES FOR TREATING CANCERS WITH EGFR MUTATIONS | NUVALENT, INC. | 2024-10-03 | — | — | US | disclosed |
| CN-114245796-B | Imidazo [1,2-a ] pyridinyl derivatives and their use in the treatment of diseases | 比奥根MA公司 | 2024-07-30 | — | — | CN | disclosed |
| US-12037346-B2 | Amino-substituted heteroaryls for treating cancers with EGFR mutations | NUVALENT, INC. (US) | 2024-07-16 | — | — | US | disclosed |
| CN-118103370-A | Fused tetracyclic quinazoline derivatives as ERBB2 inhibitors | 英莱汶公司 | 2024-05-28 | — | — | CN | disclosed |
| EP-3630759-B1 | COMPOUNDS USEFUL AS ION CHANNEL INHIBITORS FOR THE TREATMENT OF CANCER | CENTRE NAT RECH SCIENT (FR) | 2024-05-01 | — | — | EP | disclosed |
| US-20030171584-A1 | Treating p38 mediated disorders such as arthritis, Crohns disease, irritable bowel syndrome adult respiratory distress syndrome or chronic obstructive pulmonary disease. | SYNTEX (U.S.A.) LLC | 2003-09-11 | — | — | US | disclosed |
| EP-1249451-A3 | Bicyclic-substituted 4-amino-pyridopyrimidine derivatives | Pfizer Products Inc. (US) | 2003-03-12 | — | — | EP | disclosed |
| US-20030045535-A1 | Bicyclic-substituted 4-amino-pyridopyrimidine derivatives | PFIZER INC. | 2003-03-06 | — | — | US | disclosed |
| JP-2002322178-A | 4-AMINOPYRIDOPYRIMIDINE DERIVATIVE SUBSTITUTED WITH BICYCLIC GROUP | PFIZER PROD INC | 2002-11-08 | — | — | JP | disclosed |
| EP-1249451-A2 | Bicyclic-substituted 4-amino-pyridopyrimidine derivatives | Pfizer Products Inc. (US) | 2002-10-16 | — | — | EP | disclosed |
| WO-2002064594-A2 | 6-SUBSTITUTED PYRIDO-PYRIMIDINES | F. HOFFMANN-LA ROCHE AG (CH) | 2002-08-22 | — | — | WO | disclosed |
| US-5223503-A | Antitumor, anticarcinogenic agents | ELI LILLY AND COMPANY (US) | 1993-06-29 | — | — | US | disclosed |
| EP-0511792-A2 | Pyridoprimidine derivatives as antineoplastic agents | ELI LILLY AND COMPANY (US) | 1992-11-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030045535-A1 | Bicyclic-substituted 4-amino-pyridopyrimidine derivatives | CDK4, TYMP, CDK6 | PI4KA 1515/4885PI4K2B 1813/4885PI4K2A 1902/4885 |
| US-12037346-B2 | Amino-substituted heteroaryls for treating cancers with EGFR mutations | EGFR, ERBB2, ERBB3 | PI4KA 2067/4885PI4K2B 2189/4885PI4K2A 2343/4885 |
| US-20220274979-A1 | 2-METHYL-AZA-QUINAZOLINES | AZI2, DNMT1, TPMT | PI4KA 2333/4885PI4K2B 1839/4885PI4K2A 1568/4885 |
| US-12617789-B2 | Small molecular inhibitors of NF-κb inducing kinase | IRAK3, IKBKB, IKBKG | PI4KA 431/4885PI4K2B 632/4885PI4K2A 757/4885 |
| US-20250129078-A1 | ERBB2 INHIBITORS | ERBB2, ERBB3, EGFR | PI4KA 1201/4885PI4K2B 902/4885PI4K2A 1125/4885 |
| US-20030171584-A1 | Treating p38 mediated disorders such as arthritis, Crohns disease, irritable bowel syndrome adult respiratory distress syndrome or chronic obstructive pulmonary disease. | ARRB1, MAPK1, MAPK8 | PI4KA 1725/4885PI4K2B 1380/4885PI4K2A 1437/4885 |
| US-20240327435-A1 | AMINO-SUBSTITUTED HETEROCYCLES FOR TREATING CANCERS WITH EGFR MUTATIONS | EGFR, ERBB2, ERBB4 | PI4KA 934/4885PI4K2B 1433/4885PI4K2A 1234/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.